Eyenovia (NASDAQ:EYEN) Third Quarter 2024 Results
Key Financial Results
- Net loss: US$7.89m (loss widened by 7.5% from 3Q 2023).
- US$0.11 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Eyenovia Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 99%. Earnings per share (EPS) also missed analyst estimates by 3.1%.
Looking ahead, revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 79% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Eyenovia (3 don't sit too well with us) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Eyenovia might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:EYEN
Eyenovia
A commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics.
Moderate and fair value.
